: Verve Therapeutics’ stock falls 40% as analysts question safety of cholesterol-cutting gene-editing treatment

November 13, 2023

Read Time:3 Second

Analysts raise concerns about comparative effectiveness of experimental cholesterol treatment.

About Post Author

Happy

0 %

Sad

0 %

Excited

0 %

Sleepy

0 %

Angry

0 %

Surprise

0 %

0

0

More Stories

The real-estate industry is battling over how homes are listed for sale. Here’s why that matters to buyers and sellers.

The outcome of the battle could change how the average American finds for-sale home listings.

October 19, 2024

These 6 charts suggest investors should proceed with caution as S&P 500 hits 47th record high of 2024

Some say investors are growing too complacent as the bull market shows no signs of slowing down.

October 19, 2024

Here’s how much better the WNBA did financially in 2024 than in 2023

The women’s basketball league will start making an extra $140 million a year starting in 2025.

October 18, 2024

These two crypto funds may be compelling ways to bet on a Trump election win

Grayscale Investments’ Digital Large Cap Fund and Bitwise Asset Management’s Bitwise 10 Crypto Index Fund could provide attractive opportunities to...

October 18, 2024

U.S. budget deficit in fiscal 2024 swells to third-highest level on record

The federal budget deficit for fiscal 2024 was $1.8 trillion, up 8% from a year ago, as the government’s spending...

October 18, 2024

Trump tariffs would hit these stock-market sectors the hardest

S&P 500 could see a 4.7% decline next year, according to a Barclays analysis.

October 18, 2024